490519.1

PTOISBIORA (10-96

Approved for use through 10/31/99. 0MB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMITTEE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMIS control number

P Substitute for form 1449A/PTO
INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known
Application Number 08/781,296
Filing Date January 13, 1997
First Named Inventor John B. Harley et al.
Group Art Unit Not yet assigned
Examiner Name Not yet assigned

OMRF 161

of 21 Attorney Docket Number

				U.S. PATENT DOCUMEN	TS	
Examiner's Initials*	Cite No.1	Number Number	t Document Kind Code (if known		Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,554,101		Норр	11/19/85	
		4,784,942		Harley	11/15/88	
		4,865,970		Brot, et al.	09/12/89	
		5,312,752		Woltz, et al.	05/17/94	
		5,354,691		Van Eden, et al.	10/11/94	
					7	
			-			

	Initials No. Office Number							
			Foreign Patent Docum	ment		Date of Publication	Pages, Columns, Lines	
Examiner's Initials *		Office	Number ⁴				Where Relevant Passages or	
			0 113 431A	EP/		07/18/84		
			0313 156	9		04/26/89		_
			0 88/09932	PCT		06/03/88		_
			0 91/17171	PCT		1 1414/91		
			WO 91/11718	PCT		08/08/91		
			WO 94/02445	PCT		02/03/94		$\overline{}$
			WO 94/025#9	PCT		03/03/04		_

Examiner's | Date | Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through agation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Neur Gylement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on other mount of time you require to complete this form should be sent to the Chief Information Officer, Penett and Trademark Offick, Washington, DC 20231. Do NOT SERD FEES ON COMPLETE PROMISE TO THIS ADDRESS. SENT DO T. Assistant Commissioner for Penets, Penetro, DC 20231.

Not considered. Identical to the IDS of 1/21/1999 LAC 5/5/08

¹ Unique citation designation number 3 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of Jacomento View by appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4 Apricant to place a check mark here if English anguage Translation is attached.

Complete if Known

Pasent and Trademak Office: U.S. 089ARMGI
or the Pasent and Trademak Office u.S. 089ARMGI
Substitute for form 1449A/PTO

31/6 E	\	INFORM.	ATION D	ISCLOSURE	Application N	umber	08/781,296
4 \ \ \ \	<i>ا</i> لاءِ	STATEM	ENT BY	APPLICANT	Filing Date		January 13, 1997
1					First Named I	nventor	John B. Harley et al.
BB 9 199		(use as r	many sheets a	s necessary)	Group Art Un	it	Not yet assigned
	اق				Examiner Nan	ne	Not yet assigned
Sheet	₩ %	of		21	Attorney Doc	ket Number	OMRF 161
TRADEM	~						
				U.S. PA	TENT DOCUMEN	TS	
Examiner's Initials	Cite No.1	V Pater Number	t Document Kind Code ² (if known)	Name of Patente of Cited D		Date of Cited Document MM-DD-YYYY	Pages, golumns, Lines, Where Relevant Passages or Relevant Figures Appear
			1				/
		ļ					
		ļ					
-				\			
	_		1.	_			
		 		-		-/	
						/	
		1				/	
						1	
1 1		1			\ /		

				FORE	GN PATENT DOCUM	ENTE				
			Foreign Patent Docu		GIETATEIET DOCUM	-	Date of	Publication	Pages, Columns, Lines,	Γ
Examiner's Initials *	Cite No.¹	Office	Number ⁴	(ind Code ⁶ (if known)	Name of Patente Applicant of Cited De		of Cited	Document D-YYYY	Where Relevant Passages or Relevant Figures Appear	75
			WO 94/21669	PCT			09/29/9	4		
			WO 96/37225	PCT			11/26/9	В		
							-			
	_		+					_		
		_	-/	_		···		_		_
			/					$\overline{}$		
	_									
Examiner's Signature						Date Consider	ed			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation usignation number ² See attached kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the twolegter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ And of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark here y English language Translation is attached.

Burden four Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any composition in the amount of time you require to complete to the form should be sent to the Chief Information Officer, Patent and Trademark Officer, Patent and Officer, Patent and Trademark Officer, Patent and Officer, Pa

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

SUSTEMENT BY APPLICANT

PTOISS(08A (10-86 Approved for use through 10(31)99, 0M6 0551-0031 Patent and Trademark Office: U.S. 0EPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to raspond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

21

Co	mplete if Known
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART. MON PATENT LITERATURE DOCUMENTS

1		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), titly of the item (book, megazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue/number(s), publisher, cit and/or country where published	T²
		Alexander, & al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonwal Lupus Syndrome, and Experimental Nodel," <u>Arth. And Rheum.</u> 35:176-189 (1992)	
		Baneriee, et el., *Opmolete Nucleotide Sequence of the mRNA Coding for the N Protein of Vestiduar Stomatitis Virus (New Jersey Serotype),* <u>Virology</u> 437:432-438 (1984)	
		Baraket, et al., "IgG Anthodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kDSSA/Ro Protein," <u>Clin. Exp. :mmunol.</u> 89.38-45 (1992)	
		Baraket, et al., "Mapping of Ephopes on U1 snRNP Polypeptide A with Synthetic Peptides and Autoimmune Sear," Clin. Exp. Immunol. 86(1):71-78 (October, 1991)	
		Baraket, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Cupus Sers," Clin. Exp. Immunol., 81:256-262 (1990)	
		Ben-Chetrit, et al., "Isolation and Characterization of a August 3, 1997 cDNA Encoding the 60-kD Component of the Human SS-A/R Ribonucleoprotein Autoantigen," <u>J. Clin. Inv.</u> 83, 1284-1292	
		Blank, M., et al., "The Effect of the Immunomodulator Agent S101 on Interleukin-2 Production in Systemic Lupus Erythematosus ISLE) Induced in Mice by Pathogenic Anti-DNA Antiboty," Olin. Exp. Immunol. 79:443-447 (1990)	
		Blank, M., et al "Induction of SLE-Like Disease in Najor Nice with a Monoclonal anti-DNA Antibody Derivad from a Patient with Polymyositis carrying the 16/6 id," <u>J. Autoimmunity</u> 683-90 (1998)	
		Blank, M., et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti- DNA Idiotype in Naive Mice," J. Rheumatol. 17:311-317 (1990)	
		Blank, M., et al., "Induction of Experimental Anti-phospholipid Syndrom, Associated with SLE Following Immunization with Human Monocional Pathogenic Anti-DNA Idiotyse," J. <u>Autoinmunity</u> 5:495-503 (952)	

	/		
Examiner's	Date	$\overline{}$	
Signature	Considered	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of the form with next communication to applicant.

¹ Unique citation designation sumber ² See attached kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Jappases patent documents, the indication of the year of the reign of the Emperor must precode the perial number of the patent document. ¹ kind of document not the paperoprise symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the includual case. Any comments on the house to the Child Information Office, Patent and Tradehulk, Office, Washington, DC 20231. DO NOT SEND RESO ROOMETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of $1/21 \times 1999$ LAC 5/5/08

PTOISBUSA (10-96 Approved for use through 10/31/99, OMB 0951-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

Complete if Known
Application Number 08/781,296
Filing Date January 13, 1997
First Named Inventor John B. Harley et al.
Group Art Unit Not yet assigned
Examiner Name Not yet assigned

OMRF 161

(use as many sheets as necessary)

21 Attorney Docket Number

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner's	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issug/humber(s),	
Initials*	No.1	publisher, cit and/or country where published	т
-			
		Blank, M., et al., Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody	_
		SA-1 (16/6 ld+) and for Mouse Tuberculosis Antibody TB/68 (16/6 id+) Clin, Innmunct. Immunopathol. 60:471-483 (1991)	
		Bray, et al., "Epstein-Bat Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis", Arch. Neurology, 40:406-408 (1983)	
		Bray, et al., <u>Arch., Neurol.</u> , (1992)	
		Buyon, "Neonatal Lupus Syndrome," <u>Surr. Opin. In Rheum.</u> 6:523-529 (1994)	
		Chambers, J. et al., "Genomic Structure and Amino Acid Sequence demains of the Human La Autoantigen," <u>J. Biol. Chem,</u> 263:18043-18051 (1988)	
		Chambers, J., et al., "Isolation and analysis of cDNA Clones Supressing Human Lupus La Antigen," Proc. Natl. Acad. Sci. USA 82:2115-2119 (1985)	
		Chen, E.K.L., et al., "Ribonucleoprotein SS-8/La belong" to a Protein Family with Consensus Sequences for RNA Binding," Nucl. Acids Res. 17:2233-2244 (1989)	
		Cohen, "The Self, the World and Autoimmunity," Scientific American 258:52-60 (1988)	
		Craft, et al., "Murine and Drosophila B Profeins of SM snRNPS," Mol. Blat. Rep., 15:159 (1991)	
		Crone, e al., "Viral Transcription is Recessary and Sufficient for Vesicular Storiatis Virus to Inhibit Maturation of Small Nuclear	
		Ribonucleoproteins," Journal of Wiology 63(10):4172-4180 (1989)	

		\	
Examiner's	Date	$^{\prime}$	
Signature	Considered	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation pember * See attached Kinds of U.S. Patent Document. * Enter Office that issued the document. by the two-letter code (WIPO Standard ST.3.) * For Japagines penter documents, the indication of the vegar of the reign of the Emperor many precede theoretime benef of the patent document. * Kind of document when the period the period is the second standard ST. 16 if possible. * Applicant to place a check mark here if English Inargingar Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the form of time you require to complete this form should be sent to the Chief Information Office, Patent and Tradehank Office, Washington, DC 20231. DQMOT SEKD FEES OR COMMETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

Approved for use through 10/31/99, OM9 0651-0031 ork Office: U.S. DEPARTMENT OF COMMERCI

Sut	bstitute for form 1449A/PTO	
OVPEN	INFORMATION DISCLOSURE	Application Number
	STATEMENT BY APPLICANT	Filing Date
1 1 0	1	Circt Named Inventor

(use as many sheets as necessary)

Co	emplete if Known
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

		OTHER ART NON PATENT LITERATURE DOCUMENTS	_
Examiner's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
Initials*	No.1		1,
		Cunninghait, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," Journal of Impunology 141(8):2760-2766 (1988)	
		Dalldorf, et al., **ho Lymphomas of Brazilian Children*, <u>J. Am. Med. Assn.,</u> 208:1365-8 (1969)	
		Deacon, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome", Am. J. Med. 92:453-454 (1992)	
		Deacon, et al., "Detection of Bustein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Nessible Relationship with Sjogren's Syndromey, J. Pathol., 163:351-380 (1991)	
		DePolo, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genorie Sequences During Undiluted Passages: Virus Mutants Exhibiting Neally Complete Resistance to Forman's Dominant Defective Interfering Particles," <u>J. of Virology</u> 61:454-464	
		Deutscher, et al., "Molecular Analysis of the 60-kDa Human Ro Ribofuclesprotein," Proc. Natl. Acad. Sci. USA 85:9479-83 (1988)	
		Dyrberg and Oldstone, "Peptides as Probes to Study Molecula Mimicry and Virus-Induced Autoimmunity," <u>Current Topics in Microbiology</u> , and <u>Immunology</u> , 130:25-37 (1986)	
		Elkon, K., et al., "Epitope Mapping of Recombinant Held and B" Peptides Obtained by the Polymerase Chain Reaction," J. of Immun. 145:636-643 (1990)	
		Esquivel, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," J. Exp. Med., 145:1250-1263 (1977)	

-	/	_	
Examiner's	Date		
Signature	Considered		

*EXAMINER: Initial if reference conserved, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the mount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Tradequer (Nice, Washington, DC 2023). DQATO SEND FEES DO COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/19 LAC 5/5/08

¹ Unique citation designation gember ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japafese patent documents, the indication of the year of the riegin of the Emperor must precede the patent document. ³ Kind of document have papropriate symbols as indicated on the document under WIPO Standard ST. 16 if poligible. ³ Applicant to place a check mark here if English language Translation is attached.

PTOISBIOSA (10:96
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

21

Substitute for form 1449A/PTO

PE INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
FEB 9 1994 (Use as many sheets as necessary)

of

Complete if Known
Application Number
Filing Date
January 13, 1997
First Named Inventor
John B. Harley et al.
Group Art Unit
Not yet assigned
Examiner Name
Not yet assigned
Attorney Docket Number
OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issur number(s),	Г
Initials*	No.1	publisher, cit and/or country where published	Т
		Evans, *E.B. Virus Antibody in Systemic Lupus Erythematosus*Lancet. 1:1023-4 (1971)	
		Evans, et al., "Raised Ambody Titres to E.B. Virus in Systemic Lupus Erythematcsus", Moncet, 1:167-168 (1970)	
		Evans & Rothfield, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Englematosus", <u>Lancet</u> , 1:1127-1128 (1973)	
		Evans & Niederman, Epstein-Barr virus in Viral Infections in Humans, 3rd off. Evans, A.S. ed. pp 265-292 (Plenum, New York City 1989)	
		Evans, et al., "E.B.V. Antibodies in Systemia Lupus Erythematosus," <u>Lancet</u> , 325-324 (1973)	
		Ferris and Donaldson, <u>Veterinary Microbiology</u> 18(34):243-256 (1988)	
		Finerty, et al., "Protective Immunization Against Epsteig Bur Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillogovirus "xoression Vector", <u>J. Gen. Virot.</u> , 73 449-453 (1992)	
		Finerty, et al., " <u>Vaccine</u> , 12:1180-1184 (1994)	
		Fox, et al., "Potential Role of Epstein-Barry virus in Sjogren's Syndrome and Rheumatoid Arthritis", <u>J. Rheumatol.,</u> 19:18-24 (1992)	
		Fox, "Sjogren's Syndrome", <u>Current Opin. Rheum.</u> , 7:409-416 (1995)	

	/		
Examiner's	Date	X	
Signature	Considered		

*EXAMINES: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation of mber 3 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japasses patent documents, the indication of the year of the reign of the Emperor must precede the parin number of the patent document. * Sind of document with eappropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, * Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statemont: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the mount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Tradebark Office, Washington, DC 20231. DO/NOT SKND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08 Г

(use as many sheets as necessary)

PTO/SBIDSA (10-86 Approved for use through 10/31/99, 0M8 0651-0031 Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE,

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE Application Number Filing Date

Complete if Known
Application Number
G8/781,296
Filing Date
January 13, 1997
First Named Inventor
Group Art Unit
Not yet easigned
Examiner Name
Not yet assigned
Attorney Docket Number
OMRE 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

1		OTHER ART NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner's	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issug number(s),	
Initials*	No.1	publisher, cit and/or country where published	T²
		Fox, et al., Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's	
		Syndrome*,	
		Fricke, H., et al., Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunication with a Monoclonal Anti-La	
		Autoantibody," Inters. Immunol, 2:225-230 (1990)	
		Fritz, et al., "Small Nuclear U-Ribonucleoproteins in Xenopus Leevis Development," J. Mai. Biol. 178:273-285 (1984)	
1			
	_	Gaither, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" Peptides 601. Fluids 33:413-416 (1985)	_
		January Comments and Ministration of the Comments of the Comme	
		Gaither, et al., "Implications of Anti-ho/Sjogren's Syndrome a Antigen Austantibody in Normal Sera for Autoimmunity", J. Clin.	
		Cauties, et al., implications of Atter-0.5jografi a Syndronic a Attegur Accountability in Atter-0.5jografi a Syndronic a Attegur Accountability in Atter-0.5jografi a Syndronic a Attegur Accountability in Atter-0.5jografi	
		130000	
		Gallione, et al., "Nucleotide Sequences of the MRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," Virology 39-529	_
		Gallione, et al., Nucleonae Sequences of the investor and storing and visit and No. 1900.	
		1939 (1961)	
<u> </u>	-	Gergely, et al., "E.B.V. Antibodies in Systemic Lupus Erythemotosus", Lancet, 1:325-326 (1973)	
		Gargary, et al., E.B.V. Antibodies in Systemic Editor Evynenations, Earnes, 1.023-020 110707	
	_	Geysen, et al., "Strategies for Epitope Analysis Using Periode Synthesis,: J. of Immunol. Meth., 102:259-274 (1987)	
		Geysen, et al., "Strategies for Epitope Analysis Using Septile Synthesis,: 9. 01 Intitution. Weath, 102.209-274 113077	
		Gevsen, et al., "Use of Peptide Synthesis to Prove Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," Proc. Natl.	-
		Acad. Sci. USA 81:3998-4002 (1984)	
			_
		Grabowski, et al., "Drosphila AP3, a Presymptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO",	
		Nucleic Acids Research, 19(15):4297 (3987)	
		Gu, et al., <u>Dev. Biol. Stand.</u> , 84:17 - 177 (1995)	
1			

Examiner's	1	Date	7	
Signature	_	Considered		

*EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line brough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Stategent: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the denount of time you require to complete his form should be sent to the Chief Information Office, Patent and Trackenian Office, Washington, DC 20231. Op/ONT SEKO FEES OR COMMETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

^{*} Unique citation designation pumber * See attached Kinds of U.S. Patent Documents. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) * For Japaires patent documents, the indication of the vegor of the reinport of the Emperor many precede theoretime of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English Inalygage Transition is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid DMB control number

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known Application Number 08/781,296 NFORMATION DISCLOSURE January 13, 1997 Filing Date ATEMENT BY APPLICANT John B. Harley et al. First Named Inventor Group Art Unit Not yet assigned Examiner Name Not yet assigned

OMRF 161

Attorney Docket Number

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author in CAPITAL LETTERS), title of the article (when appropriate), itile/of the item (book, magezine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, or	T²
		Guldner, et N., The Journal of Immunology, 141(2):469-475 (July 15, 1988)	
		Gutierrez, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia". Cancer Res., 56:969072 (1996)	
		Haahr, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease", Ann. N. Y. Acad. Sci., 724:148-156 (1996)	
		Hahn, "Suppression of Autoimmen Diseases with Anti-idiotypic Antibodies: Muries Lupus Nephritis as a Model" Springer Seminars in Immunopathology, 7(1):25-34 984)	
- %		Hardgrave, et al. "Antibodies to Vesicolar Stomatitis Virus Proteins in Patiess with Systemic Lupus Erythematosus and in Normal Subjects," Arthritis and Rhaumatism, 36(2):962-970	
		Harley & Geither, "Autoantibodies" Rheum. Ds. Clin. N. Amer., 14:49-56 (1992)	
		Harley, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in estients with Sjogren's Syndrome", <u>Arthritis Rheum.</u> , 29:196-206 (1986)	
		Harley & James, "Review Articles: Autoepitopes in Lugos" <u>J. Lab. Clin Med.</u> , 126(6):509-516 (1995)	
		Harley, et al, "Gene Interaction at HLA-DQ Enhances Autoantiboby Production in Primary Sjorgren's Syndrome," Science 232:1145-1147 (1986)	
		Herbert, et al., Dictionary of Immunology & Ed. Blackwell Scientific Politications Oxford UK page 14 91985)	
		Heslop, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus infection by Adoptive Transfer of Gene-Modified Virus Specific T Lymphocytes", Nature Med., 2:551-555 (1996)	

	0.	/		
Examiner's		Date	$^{\prime}$	
Signature		Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on they from the time of time you require to complete this form should be sent to the Chief Intomation Officer, Patent and Tradosiary Office, Washington, DC 20231. DyNOT SEND FEES DIC COMPLETED FORMS TO THIS ADDRESS. SISN DT. Assistant manning for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation gember ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Jappaise patent documents, the indication of the year of the reign of the Engreror must precede the seeral number of the patent document. ³ Kind of document have paperpaised symbols as indicated on the document under WIPO Standard ST. 16 if position. ³ Applicant to piece a check mark here if English language Translation is attached.

FEB

PT0/58/08A (10-88 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF CONMERCE

inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid DMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(use as many sheets as necessary)

Complete if Known 08/781,296 Application Number January 13, 1997 Filing Date John B. Harley et al First Named Inventor Group Art Unit Not yet assigned Not yet assigned **Examiner Name** Attorney Docket Number **OMRF 161**

MONI PATENT LITERATURE DOCUMENTS

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	publisher, cit and/or country where published	T²
		Hinterberge *Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs. Siol. Chem., 288:2604-2618 (1983)	!
		Hollinger, et al., Seroepidemiologic Studies in Systemic Lupus Erythematosus", Bact. Proc., 171:174 (1970)	
		Horsfall, et el., "Ro and be Antigens end Maternel Anti-La Idiotype on the Surface of Myseardial Fibers in Congenital heart Block," J. of Autoimmun. 4:165-176 (1991)	
-		Huang, et al., "Human Anti-Ro Jutoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," Scand. J. Immunol., 41:220-228 (1995)	
		Huang, et al., "Immunization with Vexcular Stomatitis Virus Nucleocapsid Plotein induces Autoantibodies to the 60 kD 50 Ribonucleoprotein Particle," <u>J. Investig. Ved.</u> 43:151-158 (1995)	
		Hurd, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid", <u>Arthritis Rheum.</u> , 13:724-33 (1970)	
		inoue, et al., ""Analysis of Antibody Titers to Epstan Barr Vijds Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis", J. Infect. Dis., 164;22-24 (193f)	
		Ishii, et al., "Cycloheximide-induced Apoptosis in Burkiy Dymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection", Immunol. Cell Biol., 73:463-468 (1995)	
		James, et al., "Basic Amino Acids Predominate if the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," <u>Scand. J. Immunol.</u> 39:557-566 (1994)	
		James, et al., "Immunoglobulin Epitope Séreading and Autoimmune Dhease After Peptide Immunitation: Sm B/6'-derived PPPGMRP and PPPGIRGP Induce Spiceosome Autoimmunity", J. Exp. Med., 181-436-461 (1995)	,
		James, et al., "Inbred Mice Strains Offer in Their Capacity to Develop Splice of omal Autoimmunity After Peptide Immunization", Arthritis Rheum., 38:5226 (1995)	

Examiner's	Date	
Signature	Considered	\

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the famount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trade-park Office, Washington, DC 20231. D)/OT SEND FEES DR COMPLETE PORTINS TO THIS ADDRESS. SIST DT C. Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21 1999 LAC 5/5/08

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw li ough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation jumber 2 See attached Kinds of U.S. Patent Documents, 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 5 For Jappiese patent documents, the indication of the year of the reign of the Emperor must precise if the serial number of the patent document. 5 And of documents with the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if posity. 5 Applicant to place a check mark here if English language Translation is attached.

PT0/SS/08A (10-98 Apprived for use through 10/31/99, 0M9 0551-003/ Patent and Trademark Office: U.S. OEPARTMENT OF COMMERCE,

nder the Paperwork Reduction Act of 1895, so persons are required to respond to a collection of information unless it contains a valid OM9 control mumber

21

Substitute for form 1449A/PTO

of

NFORMATION DISCLOSURE
ATATEMENT BY APPLICANT
(use as many sheets as necessary)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.'	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issus number(s), published, cit and/or country where published	T ²
		James & Hayley. *Linear Epitope Mapping of an Sm B/B* Polypeptide*, <u>J. Immunor.</u> , 148:2074-2079 (1992)	
		James & Harley, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitape Binding Patterns", J. Immunot., 4018-4026 (1996)	
		James, et al., "Lupus Hunoral Autoimmunity After Short Peptirie Immunization", " <u>Arthrids Rheum.</u> 39:S216 (1996)	
		James & Harley, "Peptide Autonoligenicity of the Small Nuclear Ribonucleoprotein"C, "Clin. And Exp. Rheum. 13:299-305 (1995)	
		James, et al., "Sequential Autoantigenc Determinants of the Small Nuclear Ribonuclectrotein Sm D Shared by Human Lupus Autoantibodies and MRL (pr/lipr Antibodies", <u>Clin. Exp. Imunol.</u> , 98:419-46 (1994)	
		James and Harley, "Sequential Fine Specifical of the Small Nuclear Abonuclear Protein C," Clinical Res., 41(2):PA393 (1993)	
		Kalush, et al., "Neonatal Lupus Erythematosus with Cadian Infolvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus," <u>J. of Clin. Immunol.</u> 14:314-321 (1984)	
		Karameris, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome", <u>Clind Exp. Raeum</u> , 10:327-332 (1992)	
		Kaufman, et al., "In Vivo Binding of Gram-Negative Bacterial Pepildes to Hla-827: A Possible Relationship to Anklosing spondyfitis Pathogenesis", <u>UCLA School of Medicine</u> (abstract)	
		Kieff & Liebowitz, D.: Epstein-Barr virus and its replication. In Virology, and ed. Fields et al., eds. pp 1889-1921 (Paven Press, New York 1990)	

Signature	/	Consid	ered \	
AFV. 14450	 			
	ed, whether or not citation is in mount of the mount of t		109. Lraw I	ine brough citation if not in conformance

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

Date

Examiner's

^{*} Unique clastion designation prober 2 Sea statuhed Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-dates code (WIPO Standard ST.3.) 6" or Juppasse parent documents, bit indication of the year of the reign or the Emperor must precede the design unique of the patent document. 3 kind of document. 3 kind of document. 3 kind of document with appropriate symbols as indicated on the document under WIPO Standard ST.3. 16 if posible. 3 Applicant to place a check mark here if Emplish inanguage Translation is a standard.

Burden Hour Stategoff: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the includual case. Any comments on the findound to time you require to complete this form should be sent to the Chief Information Officer, Patent and Tradentin Office, Washington, CC 2023. OWN TSRNO TESS OF COMMENTED FORMS TO THIS ADDRESS. SENT OT: Assistant Commissioner for Patents, Washington, DC 2023.

AI

Г

PTO/SBIOSA (10.98 Approved for use through 10/31/89, OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCIAL

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

		Complete if Known			
J	NFORMATION DISCLOSURE	Application Number	08/781,296	_	
?	STATEMENT BY APPLICANT	Filing Date	January 13, 1997	_	
į	1	First Named Inventor	John B. Harley et al.	_	
٠,	(use as many sheets as necessary)	Group Art Unit	Not yet assigned	_	
l		Examiner Name	Not yet assigned	_	
_	11 1 1 1	Attornou Dooket Number	OMPE 161	_	

Sheek	111	of	21	Attorney Docket Number	OMRF 161	
				T NON PATENT LITERATURE DOC		
Examiner's Initials*	Cite No.'			or (in CAPITAL LETTERS), title of the art rnal, serial, symposium, catalog, etc.), da publisher, cit and/or country where p	te, page(s), volume-issu number(s),	T²
	Kitag	awa, ak al.,	Immunol. Lett., 17:249	-252 (1988)	- /	
		il, et el., "E i7-1058 (19		dy end Lymphocyte Tubuloreticular Struc	tures in Systemic Lupus Erythemetosus*, <u>Lancet</u> ,	
. Kurilla, et al., "The Lead's RNA of Vesicular Stomatis Virus is Bound by a Cellular Protein Reactive with Anti-Le Lupus Antibodies," Cell 34:837-845 (1983)						
Cuzahima, et al., "Establishmite of Anti-Epstein-Barr Virus IEBVI Cellular Immung/ by Adoptive Transfer of Virus-Specific Tlymphocytes from an HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection", Clin. Exp. Immunol. 288 (1989) Larsen, et al., "Epstein-Surr Nuclear Actigen and Viral Capaid Antigen Antibody Titers in Multiple Scienceis", Neurology, 35 (1985)						
					iters in Multiple Sclerosis", <u>Neurology</u> , 35:435-436	
				s for the Treatment of Mondolonal Epstei . Invest. Med., 17:621-675 (1994)	n-Barr Virus-Induced Lymphoproliferative Syndrome	
				clear PNAS Complexed with Proteins are ISA, 76:5493-5499 (1979)	Produced by Patients with Systemic Lupus	
		t al., *Cardi <u>d.</u> 83:793-7		osition in Condenital heart Block Associa	ted with Maternal Anti-Ro Autoantibodies," Am. J.	
				O-kDa to Ribonucleopic ein Particles by ology. 107(1):225-228 (1996)	Antibodies Associated with Cutaneous Lupus and	
	Lehm	an, et al., *S	Spreading of T-Cell Auto	mmunity to Cryptic Determinants of an	Autoantigen,* <u>Nature</u> 356:155-157 (1992)	
	Lerne	r, et al., "Ar	e snRNPs Involved in Sp	plicing?* Nature 283:220-224 (1980)		

		/	
Examiner's		Date	
Signature	/	Considered	

Not considered. Identical to the considered IDS of 1/21/19% LAC 5/5/08

^{*}EXAMINER: Initial if reference confidered, whether or not citation is in conformance with MPEP 609. Draw fins through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

^{*} Unique citation designation pember * See attached Kinds of U.S. Patent Documents. * Enter Office that : assued the document. by the two-latter code (WIPO Standard ST.3.) * For Jappaises patent documents, the indication of the vaper of the ringer to the Emperor may breeded thearistance of the patent document. * Kind of document when the patent document. * Kind of document to the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place e check mark her if English langfager Tensition is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on thebraunt of time you require to complete this form should be sent to the Chief Information Officer, Patent and Tradeburk Office, Washington, DC 20231. DQRIOT SEND FEES OR COMMETER FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patent and Tradeburk Office, Washington, DC 20231.

FEB

PT0/38/08A (10:98 Approved for use through 10/31/59, OMB 0651-0031 Pagest and Trademark Office: U.S. GEPARTMENT OF COMMERCE,

Under the Paperwork Reduction Act of 1985, so persons are required to respond to a collection of information enters it contains a wald OMS control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known
Application Number 08/791,296
Filling Date January 13, 1997
First Named Inventor John B. Harley et al.
Group Art Unit Not yet assigned
Examiner Name Not yet assigned
Attorney Docket Number 0 0MRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issus/number(s), publisher, or	T²
		Leif, *Maveck Herpes Receptor Sparks Search for KS Drug*, <u>Bio World Today</u> , 8(17):1 (1997)	
		Levitskaya, "InhibNjon of Antigen Processing by the Internel Repeat Region of the Epstein-Barr Yrus Nuclear Antigen-1", Nature, 375:885-688 (1995)	
		Maddison, et el., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Anglens in SLE," <u>Arthritis Rheum.</u> 20:819-82 (11977)	Г
		Maitland, "Frequency of E8V-DNA Detection in Sjogren's Syndrome", <u>Am. J. Mec</u> . 98:97 (1994)	
		Manfredi, et al., "Molecular Anatomy & an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," <u>J. Lab. Clin. Med.</u> 120:13-21 (1992)	
		Mariette, et al., "Detection of Epstein-Barr Vilus DNA by in Situ Hybridization and Polymerase Chain Reaction in Patients with Spogren's Syndrome", <u>Am. J. Med.</u> , 90:286-284 (1991)	
		Matter: et al., "Molecular Characterization of Ribombeleoprotey" Antigens 8ound by Antinuclear Antibodies," <u>Arthritis Rheum.</u> 25:1278-1283 (1982)	
		Mattioli, et al. "Physical Association of Two Nuclear Agrigues and Mutual Occurrence of Their Antibodies: The relationship of the SN and RNA protein (MO) Systems in SLE Sera," J. Immunol. NO 1318-1324 (1973)	
		McAllister, G., et al., "CDNA Sequence of the ray U snRNP-associated Protein N: Description of a Potential Sm Epitope," EMBO Jour. 8:1177-1181 (1989)	
		Mendlovic, S., et al., "The Genetic Regulation of the Induction of Experimental SLE," Immunology 69:228-236 (1990)	
		Mendiovic, S., et al., "The Role of Inti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice, Eur. J. Immunol. 19:729-732 (1969)	-

		/		
Examiner's		Date	$\overline{}$	
Signature	/	Considered	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line brough citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

*Unique citation designation pmber 2 See attached Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-letter code (WPO Standard ST.3.). 4 For Japapies pasted observations in indication of the year of the reign of the Emperor must precede the reignander of the patent document. *Kind of document where the patent document. *Kind of document where the patent patent is attached to the patent patent to place a check mark here if English Inaplage 7 renations in sattached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete Time will vary depending upon the needs of the included case. Any comments on the Amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trade-plan Office, 2023 in CO. 2023. DOWN SEMD FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2023.

Not considered. Identical to the considered IDS of 1/21/1999

Approved for use through 10/31/99, OM9 0951-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI rk Reduction Act of 1995, no persons are

Substitute for form 1449A/PTO

of

INFORMATION DISCLOSURE Application Number Filing Date STATEMENT BY APPLICANT First Named Inventor (use as many sheets as necessary) Group Art Unit

Complete if Known 08/781,296 January 13, 1997 John B. Harley et al. Not yet assigned Examiner Name Not yet assigned OMRF 161 Attorney Docket Number

PT0/S8/08A (10:99

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

		OTHER ART - NORTATENT EITERATORE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	_
xaminer's	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issur number(s),	
Initials*	No. 1	publisher, cit and/or country where published	
		Mendlovic S., et al., "Induction of an SLE-Like Disease in Mice by a Common Anti-DNA Idiotype," Puc. Natl. Acad. Sci. USA	_
		85:2260-2244 (1988)	
		Miller, et al., "The Role of an Autoantigen, Histidyl-tRNA Synthetase, in the Induction and Maigrenance of Autoimmunity," Proc. Nat.	_
		Acad. Sci. USA 87 9933-9937 (1990)	•
		Miller, Epstein-Barr vira, pp. 1921-1958;	-
		Miyashita, et al., "A Novel Fort of Epstein-Barr Virus Latency in Normal B Cells Vivo*, Cell, 80:593-601 (1995)	-
		Morgan, Vaccine, 10:563-571 (1992)	_
		, 10.000 57 (1002)	
		Morgan, et al., J. Med. Virol., 29:74-78 (1989)	_
		100 gar, 61 at., <u>5. 1160. VIO.</u> ,	
		Morland, et al., "Anti-idiotype and Immunosuppressent Treatment of Murine Lupus", Clin. Exp. Immunol., 83(1):126-132 (1991)	_
		instants of any state to the state of the st	
		Morshed, et al., "Increased Expression of Epstein-Barr Virus in Primary Billiary Cirrhosis Patients", Gastroenterol. Jpn., 27:751-758	_
		(1992)	
- 1		/	
		Mosier, et al., Nature 335:256-259 (1988)	_
- 1		Mosier, et al., <u>Hature</u> 333,230-237 (1300)	
- 1			
		Munves, et al., "Antibodies to Sm and RN", "Arthritis Rheum., 26: 848-853 (1983)	_
		initiatives, et al., Antibodies to sin and river, Attentis nitedin., 20. 840-853 (1983)	
			_
1		Newell & Stevens, "E.B. Virus Antibody in Systemic Lupus Erythematosus", Lencet, 1:652 (1971)	
- 1			

Examiner's		/	Date	1	·
Signature	/		Conside	red	\

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation persons * See attached Kinds of U.S. Patent Documents * Enter Office that issued the document, by the two-letter code (WIPD Standard ST.3.*). * For Japanese person documents, the indication of the year of the reing or the Emperor many precede theaperimer of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPD Standard ST. 16 if possible. * Applicant to place a check mark here if English Indigogal Translation is statehold.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the formation Officer, Patent and Tradehgark Office, Washington, CC 20231. Ogd/OT SEND FEES OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, and pathology, OC 20231.

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

PTO/SS/08A (10:98 Approved for use through 10/31/99, OM9 0651-0031

Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number

Substitute for form 1449A/PTO

P	Complete if Known			
INFORMATION DISCLOSURE	Application Number	08/781,296		
STATEMENT BY APPLICANT	Filing Date	January 13, 1997		
1998 2	First Named Inventor	John B. Harley et al.		
(use as many sheets as necessary)	Group Art Unit	Not yet assigned		
	Examiner Name	Not yet assigned		
14 of 21	Attorney Docket Number	OMRF 161		

	7	4 01		Attorney Docket Number	OMRF 161	
				T NON PATENT LITERATURE DOCUM		
Examiner's Initials*	Cite No.1	ite	m (book, magezine, jour	nor (in CAPITAL LETTERS), title of the erticle rnal, seriel, symposium, catalog, etc.), date, publisher, cit and/or country where publi	page(s), volume-issur number(s), shed	,
		Without Sjogten	's Syndrome", <u>Br. J. Rh</u>	llovirus, Epstein-Barr Virus and Herpes Virus uem., 33:317-322 (1994)	-6 in Patients with Rheumatoid Arthritis With	n or
		Nider, et al., PNA	87:9933 (1990)		7	
	1	Ohosone, et al., Small Nuclear Rib	"Molectial Cloning of cloonucleoplotein Particles	DNA Encoding Sm Autoantigen. De ivation of s," Proc. Natl. Acad. Sci. USA 66:4249-425	of a CDNA for a B Polypeptide of the U Series (1989)	s of ·
		Nucleic Acids Re	<u>s.</u> 17:1445-1455 (1989)	'	Characterization of their Protein Constituen	- 1
		Petersen, et al, * Arthritis and Syst	Altered Immune Respon- temic Lupus Erythemat	se to Glycine-Rich Sequences of Esstein-Bar sus*, <u>Arthritis Rheum.</u> , 33: 993 1000 (1990	r Nuclear Antigen-1 in Patients with Rheuma))	toid
		Petterson, et al.,	"The Structure of Mamr	malian Small Nuclear Ribony ceoproteins*, <u>J.</u>	Biol. Chem., 259:5907-5914 (1984)	T
		Pflugfelder, et al.	, "Epstien-Barr Virus and	d the Lacrimal Gland athology of Sjogren's	Syndrome", <u>Am. J. Pathol.</u> , 143:49-64 (199	(3)
		Pflugfelder, et al. Sjogren's Syndro	, "Amplification of Epste me Patients", Ophthalmo	ein-Barr Virus Genemic Sequences in Blood (ology, 97:976-984 1990)	Cells, Lactimal Glands, and Tears from Prima	гу
		Phillips & Christia	n, "Myxovirus Antibody	Increases in Human Connective Tissue Dise	ase", <u>Science</u> , 168:982-4 (1970)	
	- 1	Qualtiere & Pears	on, *Radioimmune Presi	s Erythematosus", <u>Lancet</u> , 1,1449 (1973) pitation Study Comparing the Epstein-Barr V pressed on Cells in a B-95 Virus-Transforme	irus Membrane Antigens Expressed on P3HF d Produced Culture Activated with Tumor	3-1
	$\neg \neg$		Common RNA Regiogniti		Binding of the 70K U1 snRNP Protein," Cell	

		/	
Examiner's		Date	
Signature		Considered	

** *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line quough citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the fundament of time you require to complete this form about be sent to the Chief Information Officer, Patent and Tradement Office. Weshington Co. 2023. 1. 09/107 SEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissions for Patent and Tradement Co2231.

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

¹ Unique citation designation primber ² See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanses patent documents, the indication of the year of the reign of the Emperor must precede the terial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark her if English language Translation is attached.

PTO/58/08A (10-98 Approved for use through 10/31/89. OMB 0851-0031 nark Office: U.S. DEPARTMENT OF COMMERCE

der the Peperwerk Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO

21

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of

C ₀	mplete if Known
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRE 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), titl of the	
Examiner's	Cite	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue/humber(s),	
Initials*	No.1	publisher, cit and/or country where published	T1
		Ravirajan & Staines, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adul	
	l	MRL/Mp-lpr/kg DNA-binding Monoclonal Autoantibodies* Immunology, 74:342-347 (1991)	
	l		
		Reichlin, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis end Nohritis," Clin. Exp. Immunol. 83;286-	_
		29D (1991)	
		Reichlin, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatures 52-kd Ro/SS-A in Eluates from the Heart of	
		a Child Who Died with Consenital Complete Heart Block, Arth. And Rheum. 37-1698 703 (1994)	•
		5 1557155	
	-	Renz, M., et al, "Expression of the Major Human Ribonucleoprotein (RNP) Autoanggens in Escherichia coli and their Use in an EIA for	
		Screening Sera from Patients with Autoimmune Diseases." Clin. Chem. 35:1863-1863 (1989)	
		January 655 North Value Communication Control	
	_	Reuter, et al., PNAS 83:8689-8693 (1986)	
		116000, et al., (1170 05:0055-055 11200)	
		Rhodes, et al., "Autoantibodies in Infectious Mononucleosis Have Saccificity for the Clycine-Alanine Repeating Region of the Eastein-	
		Barr Virus Nuclear Antigen*, J. Exp. Med., 163 026-1040 (1987)	
		Dail Vilds Nucleal Alfugeli , <u>3. Exp. Med.</u> , 1655/026-1040 (1987)	
		Rokeach, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," Proc. Natl. Acad. Sci. USA 85:4832-36	
		notestich, et al., Molecular Cloning of a CUNA Encoding the Suman Sm-D Autoantigen, Proc. Natl. Acad. Sci. USA 85:4832-36 (1988)	
		11300)	
		X	
- 1		Rokeach, et al., "Primary Structure of a Human Small Mudear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis", J. Bio Chem., 264:5024-30 (1989)	
		Chem., 264:5024-30 (1989)	
- !		Rose, et al., "T-Cell Regulation in Autoimmune Tryrolditis," Immonol. Reviews 55:229-314 (1981)	
ı			
	_		
		Rose, et al., "Genetic Regulation in Autoinfinune Thyroiditis," Talal N. & Autoimmunology Genetic Immunologic Virologic, and	
- 1		Clinical Aspects. New York: Academic Mess, 63-87 (1977)	
		Rose, et al., "Studies on Experimental Thyroiditis," Ann. NY Acad. Sci. 124:208-108 (1965)	

	 /	
Examiner's	Date	
Signature	Considered	

Not considered. | Identical to the considered IDS of 1/21/1 LAC 5/5/08

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line grouph citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation pumber ² See statched Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanises patent documents, the indication of the year of the reign of the Emperor must precede the yearl number of the patent document. ³ Minr of docyfrient by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ³ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to comclete. Time will vary depending upon the needs of the individual case. Any comments on thydrinount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Tradenty Office, Washington, DC 2023.1. Dydrof SEND FEES DO COMPLETE PORTIONS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2023.1.

PTOISBORA (10.96

Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: II S. OCDADTMENT OF POMMEDO

Under the Paperwork Reduction Act of 1995, no persons era to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO

21

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 08/781.296 Filing Date January 13, 1997 First Named Inventor John B. Harley et al. Group Art Unit Not yet assigned Examiner Name Not yet assigned

OMRF 161

(use as many sheets as necessary)

Attorney Docket Number OTHER ART -- NON PATENT LITERATURE DOCUMENTS

	_	THE TAIL THE PROPERTY OF BOCOMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issur number(s), publisher, cit and/or country where published	T²
		Sabbatini, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmD and Epstein- Barr Virus-Recoded Nuclear Antigen EBNA I", Eur. J. Immunol., 23:1146-1152 (1993)	1.
	<u>L</u>	Saito, et al., Setection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tipsue Biopsies from Patients with	
		Sasaki, et al., "In vitro Maripulation of Human Anti-DNA Antibody Production by Anti-Id-otypig Antibodies Conjugated with Neocarzinostatin", The Journal of Immunology, 142(4):1159-1165 (1989)	_
		Schaack, "Molecular Mileicry in HLA-B-27-Related Arthritis," Annals of Internal Medicine. 111(7):581-591 (October 1, 1989)	
		Schmauss, et al., "A Companyon of snRNP-Associated Sm-Autoantigens: Humay N, Rat N and Human B/S (abstract)", Nuc Acid Res., 17:1733-43 (1989)	
		Schoenfeld, et al., "Modulation of Experimental SLE Induced in Naive Mice by a Pathogenic Anti-DNA Idiotype (16/6 ld)," <u>Proceedings</u> of the Second International Conference on Systemic Lugus Environmentosus, Tokyo, Japan Professional Postgraduate Services 83 (1989)	
		Scheenfeld, et al., "Pathogenic Idiotypes of Autoantibodies in Autoinflumity: Lessons from New Experimental Models of SLE," FASED J. 4:2646-2651 (1990)	
		Scofied, et al., "60kD Ro/SSA Autoepitopes are Found in Regions of Homology Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatis Virus," <u>Anthritis and Rheumatism</u> 33(9),6101 (1990)	
		Scofield, et al., "Autoantigenicity of Ro/SSA Antigen is Regard to a Nucleocapsid Protein of Vesicular Stomatitis Virus", <u>Proc. Nart.</u> Acad. Sci. USA, 88:3343-3347 (1991)	
		Scofield, R., "A Common Autoepitope Near the propoxyl Termino of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," Journal of Clinical Immunology 71(6):376-388 (199)	
		Scofield, et al., "The Autoanspenicity of Moran ECKD Ro/SSA is Related to Hormologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatis Virus," Climical Research, 38(2):316A, (1930)	
·Ý		Scofield, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus", Arthritis & Rheumatism, 39(10):1664-1688 (1996)	

Examiner's Signature	Date Considered	

Not considered. Identical to the considered IDS of 1/21 LAC 5/5/08

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line grough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For JappaSes patent documents, the indication of the year of the reign of the Emperor must precede the perial number of the patent document. ² Kind of document of the pappropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant to place a check mark here if English language Translation is attached.

whit: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any mount of time you require to complete this form should be sent to the Chief information Officer, Patent and Trademyk Office, Washington, Burden Hour Statem comments on the DC 20231. DO OT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PT0/S8/08A (10:96 Approved for use through 10/31/99, QMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1895, no persons are nation unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known INFORMATION DISCLOSURE Application Number 08/781,296 STATEMENT BY APPLICANT Filing Date January 13, 1997 First Named Inventor

John B. Harley et al. (use as many sheets as necessary) Group Art Unit Not yet assigned Examiner Name Not yet assigned of Attorney Docket Number **OMRF 161**

OTHER ART. MON DATENT LITERATURE DOCUME

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the euthor (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journel, serial, symposium, catalog, etc.), date, pagets), volume-issus number(s), publisher, cit and/or country where published	T²
		Scofield, N. al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythodisticsus-Associated 60-kDa Ro Autoantigen Results in Anti-Ro Ribonucleoprotein Autoimmunity", <u>J. Immunology</u> , 4059-4066 (1996)	
		Scofield, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus end Sjogren's Syndylme", <u>Clin. Exp. Rheum.</u> , 14:321-330 (1996)	
		Scofield, "HLA-827 Birding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies", Sencet, 345:1542-1544 (1995)	
		Sculley, et el., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus end Infectious Mononucleosis to Epstein-Barr Vhus-Induced Polypeptides", <u>J. Gen. Virol.</u> , 67 2453-2258 (1986)	
		Sharpe, et al., "Isolation of cDNA Cidnes Encoding the Human Sm B/B" Aud Immune Antigen and Specifically Reaching with Human Anti-Sm Auto-", <u>FEBS Lett.</u> , 250:585-580 (1989)	
		Silikans, et al., "Human U1 snRNP-specific Protein: Complete cDM and Protein Sequence and Identification of a Multigene Family in Mammals, * <u>Nucleic Acids Res</u> , 16:8307-21 (1988)	
		Sillikens, P., et al, "cDNA Cloning of the Human U. snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP- Specific Proteins," <u>EMBO Journal</u> 6:3841-3848 (1989)	
		Singh, et al., "Decreased Incidence of Viral Infections in Over Transplant Recipients - Possible Effects of FK506?", <u>Digestive Dis. So.</u> 39:15-18 (1934)	
		Spritz, et al, "The Human U1-70K s.n. RNP Proton: cDNA Cloning Chromosomal Localization, Expression, Alternative Splicing and RNA-binding," Nucleic Acid Res. 15:10373-9141987)	
		Sturgess, A., et al., "Characteristics and Shitope Mapping of a Cloned Numan Autoantigen Le," J. linmun. 3212-3218 (1998)	
		Sumaya, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis", Ann. Neurol., 17:371-377 (1985)	

		<u>/</u>	\
Examiner's	/	Date	
Signature		Considered	

Not considered. Identical to the considered IDS of 1/21/1999 LAC 5/5/08

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line brough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-lotter code (WIPO Standard ST.3). ⁴ For Jappades patent documents, the indication of the year of the reign of the Emperor must precode the perial number of the patent document. ⁴ Kind of document is the papporaise symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the includual case. Any comments on the finour of time you require to complete this form should be sent to the Chiel Information Officer, Patent and Trasefiert, Office, Washington, OC 20231. DO SASISTEN Commissioner for Patents Ambridgen, OC 20231.

Г

PTO(S9/08A (10.95
Approved for use through 10/31/99. OM9 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Complete if Known
Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Not yet assigned

Examiner Name

Not yet assigned

OMRF 161

OMRF 161

OTHER ART MON DATENT LITERATURE DOCUMENTS

	OTHER ART NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), tips of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pagets), volume-issur number(s), publisher, cit and/or country where published	T²
	Suzuki, et N., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Indyces Local Anergy to Allogeneic and Syngenes, Tumors", <u>J. Exp. Med.</u> , 182:477-486 (1995)	
	Takeda, Y., et al. Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated JOKD Polypeptide; a comparison of regions selectively neogrized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," Chem. Abstracts 116(1): ab. N. 4803a (January 6, 192)	o.
	Tan, et al., "The 1982 Tourised Criteria for the Classification of Systemic Lupus Erytheofatosus", <u>Arthritis Rheum.</u> , 25-1271-1277 (1982)	
	Tan, et al., "Characteristics of Soluble Nuclear Antigen Precipitating with Sera Patients with Systemic Lupus Erythematosus," J Immunol. 96:484-471 (1986)	
	Tatelshi, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphebiastoid Cell Lines Obtained from Patients with Sjogren's Syndrome", <u>Arthritis Rhuem.</u> , 36:827-835 (1993)	
	Theissen, et a!., "Cloning of the Human cDNs for the U1 RNA-associated 70K Protein," <u>EM80</u> J. 5:3299-17 (1986)	
	Tigbe, <u>Production of Human Rheumatoid Factors (Rb) by SCIP Mice Transplanted with Synovial Membrane Lymphocytes</u> , presented at the Arthritis Foundation Fellows Conference, Amello Island, Plantation, Florida, December 8-10 (1989)	
	Tincari, et al., "Induction of Experimental SLE in NaivoAribe by Immunization with Human Polycional anti-DNA Antibody Carrying the 16/6 Idiotypic," <u>Clinical and Exp. Rheum.</u> 11:129-13 (1993)	
	Toda, et al., Sjogren's syndrome (SS) and Epstyn-Barr virus (EBN) reactivation. In Lacrimal Gland, Tear Film, and Dry Eye Syndrome D.A. Sullivan, ed. pp 647-650 (Plenum Press, New York 1994)	
	Tissi, et al., "Detection of Epstein-Berr Visis and Cyromegalovirus Genone in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Syylemic Lupus Erythematosus", Int. Byrch. Allergy (mmunol.), 106:235-240 (1995)	
	Tsuzuka, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S1"," <u>Arthritis & Rheumatism.</u> 38(9):abstract 726 (1995)	

Examiner's		Date	1
Signature	I /	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line brough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Butlen Nov Status Mr.: This form is attinised to take 2.0 hours to complete. Time will vary depending upon the needs of the includual case. Any comments on the influence of time to pure out to be could be sent to the Chief Information Officer, Patent and Trade-byl Officer, Washington, DC 20231. Do NOT SEND FEES OR COMPLETED FORMS TO 1-18 ADDRESS. SEND TO: Assistant Commissioner for Peterns, Wearhington, DC 20231.

Not considered. Identical to the considered IDS of 17(1/1999 LAC 5/5/08

¹ Unique citation designation sumber ² See attached Kinds of U.S. Patent Documents. ⁸ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁸ For Jappases patent documents, the indication of the year of the reign of the Emperor must precede the genal number of the patent document. ⁸ Kind of docyment by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant to place a check malk here if English language Translation is attached.

T-

PTO(SBIOBA (10-98 Approved for use through 10/31/98, OMB 0851-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE,

Under the Paperwork Raduction Act of 1895, no persons are required to respond to a collection of information unless ill centains a valid DMB control number

Substitute for form 1449A/PTO

21

NFORMATION DISCLOSURE

of

(use as many sheets as necessary)

Complete if Known
Application Number
Rifling Date
Filing Date
January 13, 1997
First Named Inventor
Group Art Unit
Examiner Name
Not yet assigned
Attorney Occket Number
OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
	Г	Include name of the author (in CAPITAL LETTERS), title of the article (when eppropriate), title of the	
Examiner's	Cite	item (book, magazine, journel, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	
Initials*	No.1	publisher, cit and/or country where published	T3
		Tzartos, et al., Autoimmunity 8:259-270 (1991)	
	_	van Dam, et al., "Noned Human snRNP Proteins B and B' Differ Only in Their Cerboxy-Terminal art", EMBO J., 8(12):3853-3860	\vdash
		(1989)	
	1		
	-	Van Venrooii, et al., "B Cell Epitopes on Nuclear Autoantigens," Arthritis and Rheumatism 37(5):608-616 (1994)	\vdash
		The state of the s	
		Venables, et al., "Persistence & Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's	├
		Syndrome*, Clin. Exp. Immunol., \$359-364 (1989)	
		2.555 564 (1565)	
		Venables, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome", J. Autoimmunity, 2:439-448 (1989)	-
		This is the first of the first	
		Virji and Heckels, "Location of a Blocking Ephope on Outer-membrane Protein III of Neisseria Gonorrhoeae by Synthetic Peptide	
		Analysis," J. of Gen. Microbiol. 135:1895-1899 (1989)	
		Voller and Bidwell, "Enzyme-Linked Immunosorbent Assay," Manual of Clinical Laboratory Immunology (Chapter 17) (1986)	
		·	
		Wait, K., et al., "Anti-Jo-1 antibodies are Directed at argenulus on served Conformational Site on Human Histidyl-tRNA	
		Synthetase, Mol. Cell Biol. Autoantibodies Autoimm 100-101 (1989)	
		Wagstaff, et al., Drugs, 47:153-205 (1994)	_
		Waltuck and Buyon, "autoantibody-associated Congenital Heart Block: Outcome in Mothers and Children," Ann. Intern. Med.	_
		120:544-551 (1994)	
-		Warner & Carp, "Multiple Scierosis Fiology - an Epstein-Barr Virus Hypothesis Med, Hypotheses, 25:93-97 (1988)	
		Trainer & Corp., months decrease though an epitem sent the Hypothesis into Hypothesis, 2000-07 (1900)	

		/			
Examiner's	1	7	Date	X	
Signature		,	Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ¹ See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japandse patent documents, the indication of the year of the reign of the Emperor must precede theoretial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark here it English language Translation is attached.

Buden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the reads of the indedust case. Any comments on the misunt of time you require to complete this form should be sent to the Chief Information Officer, Patent and Taskeria Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/2999 LAC 5/5/08 FEB

Г

PTO/SRIDBA (10-96
Approved for use through 10/31/99, OMB 0551-0031
Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

21

Substitute for form 1449A/PTO

of

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Complete if Known
Application Number
O8/791,296
Filing Date
January 13, 1997
First Named Inventor
Group Art Unit
Roman Name
Not yet assigned
Examiner Name
Not yet assigned
OMRF 161

OTHER ART MON PATENT LITERATURE DOCUMENTS

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when eppropriate), titly of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	,
Initials*	No.1	publisher, cit end/or country where published	
		Watson, et al., "Certain Properties Make Substances Antigenic," in Molecular Biology of the Gene, Fourth Edition, page 836,	
		paragraph 3, The Benjamin/Cummings Publishing Company, Menlo Park, 1987)	
		Whittingham, et al. *Epstein-Barr Virus.es an Etiological Agent in Primary Sjogren's Syndrome?, Med Hypothesis, 22:373-386	
		(1987)	
		Williams, et el., "A Repeated Proline-rich Sequence in Sm B/B" and N is a Dominant Epitone Recognized by Human and Murine	
		Autoantibodies,* J. Autointeunity 3:715-725 (1990)	
		Wilson, et al., "Association of Emphomatoid Granulomatosis With Epstein-Barr Val Infection of B Lymphocytes and Response to	
		Interferon-g2b*, Blood, 87:4531-4637 (1996)	
		Winfield, et al., "Serologic Studies in Detients with Systemic Lupus Eryther atosus and Central Nervous System Dysfunction,"	
		<u>Arthritis Rheum.</u> 21:289-294 (1978)	
		Witehsky, et al., "Chronic Thyroiditis and Autoimmunization," <u>J. Am Med. Assoc.</u> , 164:1439-1447 (1957)	
		Xie & Snyder, "Two Short Autoepitopes on the Number Dot Aftigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus", <u>Proc Natl. Acad. Sci.</u> , 92:1639-1643 (1995)	-
		Yamamoto, K., et al., "Isolation and Characterization of Complementary DNA Expressing Human U1 Small Nuclear	
		Ribonucleoprotein C Polypeptide, J. Immun. 140:317-317 (1988)	
		Yokochi, et al., "Hight Titer of Antibody to the postein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatold Arthritis	
		and Systemic Lupus Erythematosus", <u>J. Rheugratol.</u> , 16:1029-1032 (1989)	
		Zeller, et al., "Nucleocytoplasmic Distribution of snRNPs and Stockpiles snRNA-Binding Proteins During Oogenesis and Early	_
		Development in Xenopus laevis," Cell 37:425-434 (1983)	

	/		
Examiner's	Date	X	
Signature	Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Timel will vary depending upon the needs of the inheridual case. Any comments on the form of the open variety to complete this form should be sent to the Chief Information Office, Patent and Toddynd Office, Washington, DC 20231. Open SEMD FEES ON COMMETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NNot considered. Identical to the considered IDS of 1/21/1999

LAC 5/5/08ot considered. Identical to the considered IDS of 1/21/1999

LAC 5/5/08

511436 (

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

¹ Unique citation designation gember 3 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the occument, by the two-letter code (WIPO Standard ST.3). 4 For Jappalese patent documents, the indication of the year of the reign of the Emperor must precode this serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4 Applicant to place a check mark her if English language Translation is attached.

PTOISBUSA (10-95 Approved for use through 10/31/99, OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are req ired to respond to a collection of information unless it contains a valid OMB control number

		2 1 2				The state of the s		
6					49A/PTO	c	omplete if Known	7
٩	(IN/	ORN	NATIC	N DISCLOSURE	Application Number	08/781,296	/
		५ श े⊤	ATF	MENT	BY APPLICANT	Filing Date	January 13, 1997	
J	9 1998	۲J			D. A. LIOAIT	First Named Inventor	John B. Harley et al.	
	1	۱.,	(use a	s many s	heets as necessary)	Group Art Unit	Not yet assigned	
		Ø.			•	Examiner Name	Not yet assigned	
Ù	BHOMPY	2	_	of	21	Attorney Docket Number	OMRF 161	
-								
					OTHER ART	NON PATENT LITERATURE DOCUM	MENTS	
	Examiner's Initials*	Cite No.1	/	ite	m (book, magazine, journal,	CAPITAL LETTERS), title of the article serial, symposium, catalog, etc.), date, ublisher, cit and/or country where publis	page(s), volume-issug number(s),	T,
			The Me	digi Lett	er on Drugs and Therapeutic	s 37(951):55-57 (June 23, 1995)		T
				-				
							/ ·	
	` -							T
		3						+

	. /		
Examiner's		Inve	

*EXAMINER: Initial if reference considered, whether or not citation is an conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the individual case in the complete this form should be sent to the Chief Information Officer, Patent and Trademerk Office, Washington, DC 20231. DO OT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

> Not considered. Identical to considered IDS of 1/21/199 LAC 5/5/08

Signature

¹ Unique citation designation number ¹ See attached Kinds of U.S. Patant Documents, ³ Enter Office that issued the document, by the two letter code (WIPO Standard ST.3), ⁴ For Japangse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, ⁴ Applicant to place a check mark her if English bingstope (ransistion is attached.